Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 15, 2026 | Adze Biotechnology Doses First Patient in Australia in Phase 1 Trial of ADZE1.C for Advanced Melanoma | Dosing took place at The Queen Elizabeth Hospital (TQEH) in Adelaide, South Australia, under the direction of principal investigator Dr. Rachel Roberts-Thomson. This is an extraordinary moment for our company, and far more importantly, for ... |
| Dec 8, 2025 | Airwallex Secures $330M Series G at $8B Valuation, Expands to San Francisco and Accelerates AI Finance | Airwallex Confirms $330 Million Raise and Sets San Francisco as Dual Headquarters Airwallex has raised $330 million in fresh Series G funding. The company now holds an $8 billion valuation. This figure marks a sharp rise from its previous v... |
| Sep 24, 2025 | Adze Biotechnology and King’s College London Announce Clinical Collaboration in hard-to-treat Breast Cancers | Our goal is to harness the potential of ADZE1.C to reprogram the tumor microenvironment and activate systemic anti-tumor immunity. Dr. Paola Grandi, CSO Adze We urgently need innovative immunotherapies that can shift the needle for patients... |
| Sep 8, 2025 | StablecoinX Secures $530M PIPE, Expands Treasury Strategy to $890M | Key TakeawaysStablecoinX and TLGY Acquisition Corp. raised $530 million in new PIPE financing, bringing total commitments to $890 million.The capital will fund a treasury vehicle holding more than 3 billion ENA tokens, anchoring the Ethena ... |
| Sep 4, 2025 | Adze Biotechnology Secures Bellberry HREC Approval in Australia. | Adze Biotech, develops systemically-deliverable oncolytic immunotherapies, received Bellberry HREC approval for Phase I clinical trial in metastatic melanoma. This approval validates the robustness of our clinical trial design and brings us... |
| Jan 16, 2025 | ADZE Biotechnology Announces Patent Grant and Notice of Allowance from US Patent and Trademark Office | The allowed patent application and newly granted patent are part of an expanding intellectual property portfolio directed to the novel adenovirus platform. These developments expand the depth of the ADZE IP portfolio covering innovative pla... |
| Apr 8, 2024 | Paola Grandi, PhD, MBA, Joins Adze Biotechnology to Lead Pre-Clinical and Translational Research Programs. | ADZE is thrilled to welcome Dr. Paola Grandi to our team as we advance our pipeline of systemically deliverable oncolytic immunotherapies into the clinic. ADZE is thrilled to welcome Dr. Paola Grandi to our team as we advance our pipeline o... |
| Mar 16, 2023 | Adze Biotechnology Completes $6.2 Million First Closing of Series A Financing | “This first close of our Series A furthers our mission of bringing potentially life-saving treatments to patients in need.” - Sidney Hopps, Co-Founder & CEO "We look forward to working closely with our new investors and members of ... |
| Feb 7, 2023 | Adze Biotechnology Announces Orphan Drug Designation Granted to Adze-1.17-CD40L for the treatment of Malignant Glioma | Adze-1.17-CD40L is a systemically deliverable, conditionally replicative oncolytic virus that delivers recombinent human CD40 ligand locally into solid tumors. The novel Adze-1.17 oncolytic immunotherapy platform is designed for both system... |
Show more